Vantage Consulting Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Vantage Consulting Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,246	Closed	-$229K	–	221
2021 Q2	$229K	Buy	+1,246	New	+$214K	0.04%	169
2021 Q1	–	Sell	-603	Closed	-$94K	–	1821
2020 Q4	$94K	Buy	+603	New	+$77.5K	0.01%	205

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Vantage Consulting Group's ALXN Position: Q3 2021 in Review

Vantage Consulting Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,246 shares — an estimated $229K sold.

Vantage Consulting Group first reported a position in ALXN in Q4 2020 and held it in 2 quarters. The position peaked at $229K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Vantage Consulting Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Vantage Consulting Group sold 1,246 Alexion Pharmaceuticals shares in Q3 2021, an estimated $229K.
Vantage Consulting Group first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Vantage Consulting Group's Alexion Pharmaceuticals position peaked at $229K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Vantage Consulting Group's 13F filing for Q3 2021, filed 10 Nov 2021.